Monogram Orthopaedics' Next Generation Surgical Robotic System Enters Verification Phase
Portfolio Pulse from Happy Mohamed
Monogram Orthopaedics Inc. (NASDAQ:MGRM) has announced the completion of the Development Phase and the start of the Verification Phase for its next-generation autonomous surgical robotic system. The Verification Phase will involve rigorous testing and validation of the system. The company expects to complete this phase by November, in time for the shipping of its first commercialization units. Monogram has filed over 20 patent applications related to autonomous robotic execution and aims to be the first to utilize a robot-mounted sagittal saw. The company plans to start performing surgeries in 2024.
August 14, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monogram Orthopaedics' move to the Verification Phase for its next-gen autonomous surgical robotic system could potentially boost investor confidence. The company's progress towards commercialization and its plans for surgeries in 2024 could have a positive impact on its stock.
The news of Monogram Orthopaedics moving to the Verification Phase for its next-gen autonomous surgical robotic system indicates progress towards commercialization. This, along with the company's plans to start surgeries in 2024, could potentially boost investor confidence and have a positive impact on its stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100